🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Live from #ESMOBreastBCY…just got a couple of very precious gifts from my mentor & hero Ann Partridge MD, MPH ❤️ GRAZIE MILLE for what you have done for young #BreastCancer community & #oncology fellows !!! ESMO - Eur. Oncology OncoAlert #ESMOBreast25 #ESMOambassadors Dana-Farber’s Breast Oncology Center Dana-Farber

Final Analysis Ph I CHRYSALIS: Amivantamab in stage IV METexon14+ JTO & JTO CRR: - 97pts (1L=16; 2L=28, prior MET TKI=53) - ORR (all-comer) 32%, 50% in 1L, 19% prior MET TKI - mDOR 11.2m; mPFS 5.3m; mOS 15.8m - 79% rash, 72% IRRs OncoAlert #LCSM jto.org/article/S1556-…

Still too much ADT alone… In this VA study of 6216 veterans with de novo mHSPC: 📅 2022... and still 37% got only ADT! 🔵Combo therapy = longer OS (40.3 vs 33.0 mo) 🔵Not only biology, also delivery does matter! JAMA Network Open OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation

Unveiling the paradigm shift: systemic treatment strategies in small, node-negative breast cancer Should we recommend adjuvant therapy in T1a–T1b tumors? Great review👇 nature.com/articles/s4152…

Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.

Last post from #ESMOBreast25…I’m deeply grateful & really honored for the opportunity to chair together with Dr. Shani Paluch-Shimon the #ESMOBreastBCY sessions…2 days that have brought together the #oncology community caring for #BreastCancer in young women! ESMO - Eur. Oncology OncoAlert

Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib. Thanks Millie Das MD for the heads up. #ATS2025 #RadOncMeetsTargetedTherapy

Back home after an amazing #ESMOBreast25 Grateful to speak in two panels on BRCA mutations & IBC. Honored to share the stage with such brilliant experts. Let’s keep pushing for better care🩷 ESMO - Eur. Oncology Wendy Woodward MDPhD Breast Surgeon Europa Donna Europa Donna Albania OncoAlert

🔥 Annals of Oncology 🆙 ✅ Collection of articles from Japanese authors 🎯This collection includes the winner of the JSMO 2025 Award, junko tanizaki 🎯Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary OncoAlert annalsofoncology.org/content/jsmo

❓What H/O programs sponsor What visas❓ This year, Dr. Xia (Yaya) Wu Tufts University spearheaded a Visa project to survey this for IMG applicants! Stay tuned for data release from Visa and Advocacy Committee on 5/30 IMG Oncologists Hem-Onc Fellows Network #ASCO25 #IMGoncCoP

⚡️ Identification of a panel of lncRNAs derived from urinary extracellular vesicles as non-invasive diagnostic biomarkers for bladder cancer #BladderCancer sciencedirect.com/science/articl….

Here’s the most recent #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (May 12th-18th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Huge congrats to Cancer at Cedars-Sinai 2nd yr heme/onc fellow Dr. Louisa Liu for her 2025 Conquer Cancer, the ASCO Foundation #YIA 🙌❗️❗️Way to represent Cedars-Sinai. Proud to serve as her mentor for this award. As a former class of 2022 ASCO #CCF #CDA recipient, I know how impactful this award will be

Dr. Elez Vall d'Hebron Vall d’Hebron Institute of Oncology (VHIO) updated results of BREAKWATER #1L #BRAFV600E MT #mCRC ➡️ PFS 12.8 mos/OS 30.3 mos FOLFOX-EC vs PFS 7. 1 mos/OS 15.1 mos SOC, impressive OS benefit even w/EC access in control arm. Activity shown for EC alone arm as well #ASCO25 OncoAlert

Dr. Strickler PhIb CodeBreak101 in 2L+ #KRASG12C MT #mCRC ➡️ n=40 at Soto 960 mg QD + standard dose FOLFIRI + pmab (50% had PD w/irino before) ORR 55% w/prior irino PD, PFS 8.2 mos, OS 15.6 mos. No new safety signals. PhIII underway CodeBreaK 301 #ASCO25 OncoAlert

Dr. Haas 5-year update of KN-564 of adj pembro vs. surveillance in localized #RCC at high-risk of recurrence ➡️ DFS and OS benefits maintained w/new landmark data shown. Survival benefits seen across key subgroups #ASCO25 OncoAlert

Final results from PhIII rand CM-901 #1L #mUC cis-ineligible of nivo/ipi vs gem/carbo ➡️ primary endpoint not met, no sig diff in OS b/t arms even in PD-L1>1%, similar ORR b/t arms, higher CR rate w/nivo/ipi #ASCO25 OncoAlert

Dr. Xu rand PhII JMT101 (potent anti-EGFR Ab) + irino/SG001(PD-1 inh) vs rego #3L #RAS/BRAF WT #mCRC ➡️ ORR 44% vs 3%, median PFS 5.7 vs 2.9 mos, in favor of triplet, benefits independent of prior anti-EGFR tx. PhIII trial planned. OS immature #ASCO25 OncoAlert

Frank Sinicrope, MD plenary session PhIII #ATOMIC adj 6 mos FOLFOX +/- atezo add’l 6 mos in #MSI-H stage III #coloncancer ➡️ median F/U 37.2 mos, 3-yr DFS 86.4% vs 76.6% (HR 0.5) in favor of atezo arm, OS immature may be confounded w/post-PD IO, 2 TRAE G5 atezo arm #ASCO25 OncoAlert

Yelena Y. Janjigian MD plenary session PhIII MATTERHORN periop FLOT +/- durva (up to 1 yr) in stage II-IVa G/GEJ adenoCA (90% PD-L1>1) ➡️ 29% reduction in PD or death, superior EFS (HR 0.71) w/durva arm. pCR 19% vs 7% (52% finished adj durva, 61% finished adj FLOT). #ASCO25 OncoAlert